10
Aug
2010
Posted in I - Series A, Q - 3Q10, R - NORTH WEST, X - Antiviral, X - Influenza, X - Vaccines, XX - MA
Visterra (Cambridge, MA) a development-stage company focused virus-glycan docking to derive products for the prevention, treatment and diagnosis of influenza and other infectious diseases, closed a $6M Series A financing. Participants include Flagship Ventures, Lux Capital and Polaris Venture Partners.
12
Apr
2010
Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, XX - CA
Juvaris BioTherapeutics (Burlingame, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing, bringing the total round to $25M. Participants include Kleiner Perkins Caufield & Byers, SV Life Sciences and an undisclosed corporate partner.
22
Mar
2010
17
Mar
2010
Posted in I - Series A, Q - 1Q10, R - INTERNATIONAL, X - Immunology, X - Influenza, X - Vaccines
Immune Targeting Systems (United Kingdom) a clinical-stage biopharma focused on synthetic vaccines for seasonal influenza strains, closed a $13.2M Series A financing, bringing the total round to $20.2M. Participants include Novartis Venture Funds, HealthCap, Truffle Capital and London Technology Fund.
27
Jan
2010
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Antiinfective, X - Asthma, X - COPD, X - Influenza, X - RSV, X - Respiratory, XX - MA
Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture [...]
02
Nov
2009
Posted in I - Series B, Q - 3Q09, R - WEST, X - Influenza, X - Leukemia, X - Vaccines, X - Veterinary, XX - CA
Juvaris BioTherapeutics (Pleasanton, CA) a clinical-stage biopharma company focused on adjuvanted vaccines for seasonal flu and immunotherapeutics for Leukemia and animal health, closed a $12.5M Series B financing. Participants include SV Life Sciences and Kleiner Perkins Caufield & Byers.
*Estimated first close of round
21
Oct
2009
06
Aug
2009
Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Influenza, X - Osteoporosis, XX - CA
Zosano Pharma (Fremont, CA) a clinical-stage device company focused on a transdermal microprojection delivery system for needle-free administration therapeutic peptides, small molecules and vaccines. Participants include Nomura Phase4 Ventures, New Enterprise Associates, HBM BioVentures and ProQuest Investments.
10
May
2009
17
Feb
2009